



03-16-06

New \$

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/759520-Conf. #7043	
	Filing Date	January 16, 2004	
	First Named Inventor	Ganesh Venkataraman	
	Art Unit	2863	
	Examiner Name	T. S. Lau	
Total Number of Pages in This Submission		Attorney Docket Number	M0656.70089US02

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form PTO-1449; Check in the amount of \$180.00; Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	Janice A. Vatland, Ph.D.		
Date	March 14, 2006	Reg. No.	52,318

xndd

Certificate of Express Mailing Under 37 CFR 1.10

Express Mail Label No. EV717202111US Dated: March 14, 2006



Express Mail Label No.: EV717202111US

Date of Deposit: March 14, 2006

DOCKET NO.: M0656.70089US02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Venkataraman et al.  
Serial No.: 10/759,520  
Confirmation No.: 7043  
Filed: January 16, 2004  
For: METHODS FOR THE COMPOSITIONAL ANALYSIS OF  
POLYMERS  
Examiner: Tung S. Lau  
Art Unit: 2863

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

995160.1

03/17/2006 JBALINAN 00000080 10759520

01 FC:1806

180.00 0P

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Docket No.</u>
09/384,959	08-27-1999	Sasisekharan et al.	*M0656.70046US00
09/557,997	04-24-2000	Venkataraman et al.	*M0656.70055US00
11/171,490	06-29-2005	Chandrasekaran et al.	*M0656.70107US01
11/187,571	07-22-2005	Liu et al.	*M0656.70086US02
11/191,144	07-27-2005	Sasisekharan et al.	*M0656.70046US01
11/229,488	09-15-2005	Berry et al.	*M0656.70109US01
11/244,826	10-06-2005	Bosques et al.	*M0656.70106US02
11/332,766	01-12-2006	Sasisekharan et al.	*M0656.700113US02

\*A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

### PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

Serial No.: 10/759,520  
Conf. No.: 7043

- 3 -

Art Unit: 2863

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:

  
Janice A. Vatland, Ph.D., Reg. No. 52,318  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: M0656.70089US02

Date: March 14, 2006

xNDDx

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/759,520

ATTY. DOCKET NO.: M0656.70089US02

FILING DATE: January 16, 2004

CONFIRMATION NO.: 7043

APPLICANT: Venkataraman et al.

GROUP ART UNIT: 2863

EXAMINER: Tung S. Lau

Sheet 1 of 13

MAR 14 2006

**U.S. PATENT DOCUMENTS**

Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
	Number	Kind Code		
	4,303,651		Lindahl et al.	12-01-1981
	4,486,420		Lormeau et al.	12-04-1984
	4,692,435		Lormeau et al.	09-08-1987
	4,784,820		Kavesh	11-15-1988
	5,110,918		Casu et al.	05-05-1992
	5,284,558		Linhardt et al.	02-08-1994
	5,389,618		Debrie	02-14-1995
	5,569,366		Chen et al.	10-29-1996
	5,597,811		Gruber	01-28-1997
	5,607,859		Biemann et al.	03-04-1997
	5,759,767		Lakowicz et al.	06-02-1998
	5,767,269		Hirsh et al.	06-16-1998
	5,968,822		Pecker et al.	10-19-1999
	6,190,522		Haro	02-20-2001
	6,190,875	B1	Ben-Artzi et al.	02-20-2001
	6,217,863		Godavarti et al.	04-17-2001
	6,368,642		Kreiberg et al.	04-09-2002
	6,429,302		Kennedy	08-06-2002
	6,569,366		Toyohara et al.	05-27-2003
	6,962,699		Pojasek et al.	11-08-2005
	2002-0172961		Schneider et al.	11-21-2002
	2003-0008326		Sem et al.	01-09-2003
	2003-0096281		Venkataraman et al.	05-22-2003
	2003-0203385		Venkataraman et al.	10-30-2003
	2003-0219830		Venkataraman et al.	11-27-2003
	2004-0087543		Shriver et al.	05-06-2004
	2004-0091471	A1	Myette et al.	05-13-2004
	2004-0091472	A1	Pojasek et al.	05-13-2004
	2004-0092037	A1	Sasisekharan et al.	05-13-2004
	2004-0147033		Shriver et al.	07-29-2004
	2004-0204869		Venkataraman et al.	10-14-2004
	2004-0214228		Venkataraman et al.	10-28-2004

EXAMINER:

DATE CONSIDERED:

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520		ATTY. DOCKET NO.: M0656.70089US02	
				FILING DATE: January 16, 2004		CONFIRMATION NO.: 7043	
				APPLICANT: Venkataraman et al.			
				GROUP ART UNIT: 2863		EXAMINER: Tung S. Lau	
Sheet	2	of	13				

		2005-0065738		Raguram	03-24-2005
		2005-0214276	A9	Myette et al.	09-29-2005
		2005-0227320	A1	Pojasek et al.	10-14-2005
		2005-0233401	A1	Liu et al.	10-20-2005
		2005-0233402		Liu et al.	10-20-2005
		2005-0233419	A1	Pojasek et al.	10-20-2005
		2005-0266067		Sengupta et al.	12-01-2005
		2006-0024664	A1	Sasisekharan et al.	02-02-2006

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	*	EP	0 114 589	B1	President and Fellows of Harvard College	09-23-1987	
	*	EP	0 244 236	A2	Novo Industri A/S	11-04-1987	
	*	EP	0 394 971	A1	KabiVitrum AB	10-31-1990	
	*	EP	0 747 705	A1	Bayer AG	12-11-1996	
	*	WO	92/01003	A1	Board of Regents, The University of Texas System	01-23-1992	
	*	WO	93/05167	A1	Children's Medical Center Corporation	03-18-1993	
	*	WO	93/10450	A1	Glyko, Inc.	05-27-1993	
	*	WO	93/15406	A1	Imperial College of Science, Technology & Medicine	08-05-1993	
	*	WO	96/13606		Cancer Research Campaign Technology Limited	05-09-1996	
	*	WO	96/28169	A1	Medical College of Hampton Roads	09-19-1996	
	*	WO	98/04902	A1	The State of Oregon	02-05-1998	
	*	WO	99/28462	A2	Genentech, Inc.	06-10-1999	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	[No Author Listed] Aqua Peptides. Online at <a href="http://www.sigmaaldrich.com">http://www.sigmaaldrich.com</a> . Printed 7/8/2005.	
	*	[No Author Listed] MIT News Office. "MIT Tool Impacts Multi-Billion Dollar Drug." Online at <a href="http://www.sciencedaily.com">http://www.sciencedaily.com</a> . Printed 9/21/00.	
	*	"Antigen" definition, Merriam-Webster online dictionary, 2006, on the world wide web at <a href="http://www.merriam-webster.com/dictionary/antigen">http://www.merriam-webster.com/dictionary/antigen</a> , 1 page.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520		ATTY. DOCKET NO.: M0656.70089US02	
				FILING DATE: January 16, 2004		CONFIRMATION NO.: 7043	
				APPLICANT: Venkataraman et al.			
				GROUP ART UNIT: 2863		EXAMINER: Tung S. Lau	
Sheet	3	of	13				

	*	"Carbohydrate" definition, Merriam-Webster online dictionary, 2006, on the world wide web at <a href="http://www.merriam-webster.com/dictionary/carbohydrate">http://www.merriam-webster.com/dictionary/carbohydrate</a> , 1 page.	
	*	"Saccharide" definition, Merriam-Webster online dictionary, 2006, on the world wide web at <a href="http://www.merriam-webster.com/dictionary/saccharide">http://www.merriam-webster.com/dictionary/saccharide</a> , 1 page.	
	*	ACHUR et al., Characterization of proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans of the intervillous spaces that mediate the adherence of Plasmodium falciparum-infected erythrocytes to the placenta. J Biol Chem. 2000 Dec 22;275(51):40344-56.	
	*	BEHR et al., Quantification of isomers from a mixture of twelve heparin and heparan sulfate disaccharides using tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(18):2553-62.	
	*	BELANGER et al., Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate. 1995 Oct;27(4):187-97.	
	*	BENGTTSSON et al., Interaction of lipoprotein lipase with native and modified heparin-like polysaccharides. Biochem J. 1980 Sep 1;189(3):625-33.	
	*	BERRY et al., Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor-2 biological activity through different fibroblast growth factor receptors. FASEB J. 2001 Jun;15(8):1422-4.	
	*	BERRY et al., Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor-2 biological activity through different fibroblast growth factor receptors. FASEB Journal express article 10.1096/fj.00-0661fje. Published onlien April 6, 2001. 19 pages.	
	*	BOURIN et al., Glycosaminoglycans and the regulation of blood coagulation. Biochem J. 1993 Jan 15;289 ( Pt 2):313-30.	
	*	BROCKHAUSEN et al., Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95.	
	*	CALLAS et al., Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoid. Semin Thromb Hemost. 1993;19 Suppl 1:49-57.	
	*	CASU et al., Structural characterization of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3:17-25.	
	*	CASU et al., Characterization of sulfation patterns of beef and pig mucosal heparins by nuclear magnetic resonance spectroscopy. Arzneimittelforschung. 1996 May;46(5):472-7.	
	*	COINTE et al., Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties. Glycobiology. 2000 May;10(5):511-9.	
	*	CONRAD et al., Structure of heparan sulfate and dermatan sulfate. Ann N Y Acad Sci. 1989;556:18-28.	
	*	DAI et al., HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem. 2005 Dec 2;280(48):40066-73.	
	*	DESAI et al., Molecular weight of low molecular weight heparins by 13C nuclear magnetic resonance spectroscopy. Carbohydr Res. 1994 Mar 4;255:193-212.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520	ATTY. DOCKET NO.: M0656.70089US02
				FILING DATE: January 16, 2004	CONFIRMATION NO.: 7043
				APPLICANT: Venkataraman et al.	
				GROUP ART UNIT: 2863	EXAMINER: Tung S. Lau
Sheet	4	of	13		

*	DESAI et al., Specificity studies on the heparin lyases from <i>Flavobacterium heparinum</i> . <i>Biochemistry</i> . 1993 Aug 17;32(32):8140-5.
*	DIETRICH et al., Enzymic degradation of heparin. A glucosaminidase and a glycuronidase from <i>Flavobacterium heparinum</i> . <i>Biochemistry</i> . 1969 May;8(5):2089-94.
*	DIETRICH et al., Sequential degradation of heparin in <i>Flavobacterium heparinum</i> . Purification and properties of five enzymes involved in heparin degradation. <i>J Biol Chem</i> . 1973 Sep 25;248(18):6408-15.
*	DULL et al., Lung endothelial heparan sulfates mediate cationic peptide-induced barrier dysfunction: a new role for the glycocalyx. <i>Am J Physiol Lung Cell Mol Physiol</i> . 2003 Nov;285(5):L986-95.
*	DUTEIL et al., Identification of heparin oligosaccharides by direct coupling of capillary electrophoresis/ionspray-mass spectrometry. <i>Rapid Commun Mass Spectrom</i> . 1999;13(19):1889-98.
*	ERNST et al., Enzymatic degradation of glycosaminoglycans. <i>Crit Rev Biochem Mol Biol</i> . 1995;30(5):387-444.
*	FORNO et al., N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. <i>Eur J Biochem</i> . 2004 Mar;271(5):907-19.
*	GACESA et al., Enzymic degradation of alginates. <i>Int J Biochem</i> . 1992 Apr;24(4):545-52.
*	GANDRA et al., Anticoagulant sulfated glycosaminoglycans in the tissues of the primitive chordate <i>Styela plicata</i> (Tunicata). <i>Glycobiology</i> . 2000 Dec;10(12):1333-40.
*	GAUCHER et al., STAT: a saccharide topology analysis tool used in combination with tandem mass spectrometry. <i>Anal Chem</i> . 2000 Jun 1;72(11):2331-6.
*	GU et al., Purification, characterization and specificity of chondroitin lyases and glycuronidase from <i>Flavobacterium heparinum</i> . <i>Biochem J</i> . 1995 Dec 1;312 ( Pt 2):569-77.
*	HABUCHI et al., Diversity and functions of glycosaminoglycan sulfotransferases. <i>Biochim Biophys Acta</i> . 2000 Apr 6;1474(2):115-27.
*	HASHIMOTO et al., Unsaturated glucuronyl hydrolase of <i>Bacillus</i> sp. GL1: novel enzyme prerequisite for metabolism of unsaturated oligosaccharides produced by polysaccharide lyases. <i>Arch Biochem Biophys</i> . 1999 Aug 15;368(2):367-74.
*	HORNER, Heterogeneity of rat skin heparin chains with high affinity for antithrombin. <i>Biochem J</i> . 1987 Jun 15;244(3):693-8.
*	HOVINGH et al., Specificity of flavobacterial glycuronidases acting on disaccharides derived from glycosaminoglycans. <i>Biochem J</i> . 1977 Aug 1;165(2):287-93.
*	HRICOVINI et al., Structure of heparin-derived tetrasaccharide complexed to the plasma protein antithrombin derived from NOEs, J-couplings and chemical shifts. <i>Eur J Biochem</i> . 1999 May;261(3):789-801.
*	HUANG et al., Low-molecular-weight heparins. <i>Hematol Oncol Clin North Am</i> . 1998 Dec;12(6):1251-81, vi-vii.
*	HUIGE et al., Force field parameters for sulfates and sulfamates bases on <i>Ab Initio</i> calculations: Extensions of AMBER and CHARMM fields. <i>J Comp Chem</i> . 1995;16(1):56-79.
*	HULETT et al., Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. <i>Nat Med</i> . 1999 Jul;5(7):803-9.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520	ATTY. DOCKET NO.: M0656.70089US02
				FILING DATE: January 16, 2004	CONFIRMATION NO.: 7043
				APPLICANT: Venkataraman et al.	
				GROUP ART UNIT: 2863	EXAMINER: Tung S. Lau
Sheet	5	of	13		

*	JOHANNES et al., Sugars related to heparin inhibit tumors: Study of mice suggests the anticlotting drug may be used for cancer. Wall Street Journal. Jan 22, 2002. B3.
*	JOHNSON et al., Endothelial cells preparing to die by apoptosis initiate a program of transcriptome and glycome regulation. FASEB J. 2004 Jan;18(1):188-90.
*	JONES et al., Octamer sequencing technology: Optimization using fluorescent chemistry. ABRF News. 1998;9(2):1-24.
*	KAJI et al., Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat Biotechnol. 2003 Jun;21(6):667-72. Abstract Only.
*	KAKEHI et al., Analysis of glycoproteins, glycopeptides and glycoprotein-derived oligosaccharides by high-performance capillary electrophoresis. J Chromatogr A. 1996 Jan 12;720(1-2):377-93.
*	KISHIBE et al., Structural requirements of heparan sulfate for the binding to the tumor-derived adhesion factor/angiomodulin that induces cord-like structures to ECV-304 human carcinoma cells. J Biol Chem. 2000 May 19;275(20):15321-9.
*	KJELLEN et al., Proteoglycans: structures and interactions. Annu Rev Biochem. 1991;60:443-75.
*	KÜSTER et al., 18O-labeling of N-glycosylation sites to improve the identification of gel-separated glycoproteins using peptide mass mapping and database searching. Anal Chem. 1999 Apr 1;71(7):1431-40.
*	LANDBERG et al., Carbohydrate composition of serum transferrin isoforms from patients with high alcohol consumption. Biochem Biophys Res Commun. 1995 May 16;210(2):267-74.
*	LANDBERG et al., Changes in glycosylation of human bile-salt-stimulated lipase during lactation. Arch Biochem Biophys. 2000 May 15;377(2):246-54.
*	LAPADULA et al., Congruent strategies for carbohydrate sequencing. 3. OSCAR: an algorithm for assigning oligosaccharide topology from MS(n) data. Anal Chem. 2005 Oct 1;77(19):6271-9.
*	LIND et al., Biosynthesis of heparin/heparan sulfate. Identification of a 70-kDa protein catalyzing both the D-glucuronosyl- and the N-acetyl-D-glucosaminyltransferase reactions. J Biol Chem. 1993 Oct 5;268(28):20705-8.
*	LINDAHL et al., Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex. J Biol Chem. 1999 Oct 22;274(43):30631-5.
*	LOPEZ et al., Microheterogeneity of the oligosaccharides carried by the recombinant bovine lactoferrin expressed in Mamestra brassicae cells. Glycobiology. 1997 Jul;7(5):635-51.
*	LYON et al., Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol. 1998 Nov;17(7):485-93.
*	MA et al., Carbohydrate analysis of a chimeric recombinant monoclonal antibody by capillary electrophoresis with laser-induced fluorescence detection. Anal Chem. 1999 Nov 15;71(22):5185-92.
*	MAIMONE et al., Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem. 1990 Oct 25;265(30):18263-71. Erratum in: J Biol Chem 1991 Aug 5;266(22):14830.
*	MANZI et al., Exploring the glycan repertoire of genetically modified mice by isolation and profiling of the major glycan classes and nano-NMR analysis of glycan mixtures. Glycobiology. 2000 Jul;10(7):669-89.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520		ATTY. DOCKET NO.: M0656.70089US02	
				FILING DATE: January 16, 2004		CONFIRMATION NO.: 7043	
				APPLICANT: Venkataraman et al.			
				GROUP ART UNIT: 2863		EXAMINER: Tung S. Lau	
Sheet	6	of	13				

*	MARCINIAK, Differential role of fractionated heparin in antithrombin-III proteolysis. Blood. 1982 Mar;59(3):576-81.
*	MASCELLANI et al., Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate. Biochem J. 1993 Dec 15;296 ( Pt 3):639-48.
*	MCLEAN et al., Action of heparinase II on pig mucosal heparin. Proc. Of the 8 <sup>th</sup> International Symposium on Glycoconjugates. 1985. Abstract 73-74.
*	MCLEAN et al., Flavobacterium heparinum 2-O-sulphatase for 2-O-sulphato-delta 4,5-glycuronate-terminated oligosaccharides from heparin. Eur J Biochem. 1984 Dec 17;145(3):607-15.
*	MECHREF et al., Structural investigations of glycoconjugates at high sensitivity. Chem Rev. 2002 Feb;102(2):321-69.
*	MECHREF et al., Matrix-assisted laser desorption/ionization mass spectrometry of acidic glyconjugates facilitated by the use of spermine as a co-matrix. J Am Soc Mass Spectrom. 1998;9:1293-302.
*	MERRY et al., Highly sensitive sequencing of the sulfated domains of heparan sulfate. J Biol Chem. 1999 Jun 25;274(26):18455-62.
*	MORELLE et al., Glycomics and mass spectrometry. Curr Pharm Des. 2005;11(20):2615-45. Abstract Only.
*	MORGENSTERN et al., Chondroitin sulphate proteoglycans in the CNS injury response. Prog Brain Res. 2002;137:313-32. Abstract Only.
*	MULLOY et al., Assignment of the 1H-n.m.r. spectra of heparin and heparan sulphate. Carbohydr Res. 1987 Dec 15;170(2):151-65.
*	NADANAKA et al., The unusual tetrasaccharide sequence GlcA beta 1-3GalNAc(4-sulfate)beta 1-4GlcA(2-sulfate)beta 1-3GalNAc(6-sulfate) found in the hexasaccharides prepared by testicular hyaluronidase digestion of shark cartilage chondroitin sulfate D. Glycobiology. 1997 Mar;7(2):253-63.
*	NADER et al., Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3565-9.
*	NAGASAWA et al., Anticoagulant effect of low molecular weight fractions derived from a chemically modified heparin. Thromb Res. 1991 Nov 15;64(4):521-5.
*	NESHEIM et al., Dependence of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity-purified heparin. J Biol Chem. 1986 Mar 5;261(7):3214-21.
*	NORGARD-SUMNICHT et al., Exploring the outcome of genetic modifications of glycosylation in cultured cell lines by concurrent isolation of the major classes of vertebrate glycans. Glycobiology. 2000 Jul;10(7):691-700.
*	PETITOU et al., Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature. 1999 Apr 1;398(6726):417-22.
*	PETITOU et al., Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics. Bioorg Med Chem Lett. 1999 Apr 19;9(8):1161-6.
*	PIXLEY et al., Preparation of highly stable antithrombin-sepharose and utilization for the fractionation of heparin. Thromb Res. 1982 Apr 15;26(2):129-33.
*	PLAAS et al., Glycosaminoglycan sulfation in human osteoarthritis. Disease-related alterations at the non-reducing termini of chondroitin and dermatan sulfate. J Biol Chem. 1998 May 15;273(20):12642-9.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520		ATTY. DOCKET NO.: M0656.70089US02	
				FILING DATE: January 16, 2004		CONFIRMATION NO.: 7043	
				APPLICANT: Venkataraman et al.			
				GROUP ART UNIT: 2863		EXAMINER: Tung S. Lau	
Sheet	7	of	13				

*	PRABHAKAR et al., Chondroitinase ABC I from <i>Proteus vulgaris</i> : cloning, recombinant expression and active site identification. <i>Biochem J.</i> 2005 Feb 15;386(Pt 1):103-12.
*	PRABHAKAR et al., Biochemical characterization of the chondroitinase ABC I active site. <i>Biochem J.</i> 2005 Sep 1;390(Pt 2):395-405.
*	RAHBEEK-NIELSEN et al., Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. <i>J Mass Spectrom.</i> 1997 Sep;32(9):948-58.
*	RAMAN et al., Structural insights into biological roles of protein-glycosaminoglycan interactions. <i>Chem Biol.</i> 2005 Mar;12(3):267-77.
*	RAMAN et al., Glycomics: an integrated systems approach to structure-function relationships of glycans. <i>Nat Methods.</i> 2005 Nov;2(11):817-24.
*	RAMAN et al., Advancing Glycomics: Implementation Strategies at the Consortium for Functional Glycomics. <i>Glycobiology.</i> 2006 Feb 14; [Epub ahead of print]
*	RAY et al., Glycoprotein Glycan Analysis: A new USP General Chapter. Slides of a lecture presented at the USP Conference on Biological and Biotechnological Drug Substances and Products. Crystal City, Virginia. November 20, 2003.
*	RAZI et al., Structural and functional properties of heparin analogues obtained by chemical sulphation of <i>Escherichia coli</i> K5 capsular polysaccharide. <i>Biochem J.</i> 1995 Jul 15;309 ( Pt 2):465-72.
*	RUSH et al., Microheterogeneity of erythropoietin carbohydrate structure. <i>Anal Chem.</i> 1995 Apr 15;67(8):1442-52.
*	RUSH et al., Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis. <i>Anal Chem.</i> 1993 Jul 15;65(14):1834-42.
*	SAMPAIO et al., Effect of monensin on the sulfation of heparan sulfate proteoglycan from endothelial cells. <i>J Cell Biochem.</i> 1992 Sep;50(1):103-10.
*	SASAKI et al., Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. <i>Biochemistry.</i> 1988 Nov 15;27(23):8618-26.
*	SHUKLA et al., A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. <i>Cell.</i> 1999 Oct 1;99(1):13-22.
*	SIMEON et al., Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). <i>J Invest Dermatol.</i> 2000 Dec;115(6):962-8.
*	SOBEL et al., Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. <i>Circulation.</i> 1996 Mar 1;93(5):992-9.
*	SUGAHARA et al., Novel sulfated oligosaccharides containing 3-O-sulfated glucuronic acid from king crab cartilage chondroitin sulfate K. Unexpected degradation by chondroitinase ABC. <i>J Biol Chem.</i> 1996 Oct 25;271(43):26745-54.
*	TOIDA et al., Enzymatic preparation of heparin oligosaccharides containing antithrombin III binding sites. <i>J Biol Chem.</i> 1996 Dec 13;271(50):32040-7.
*	TSENG et al., Catalog-library approach for the rapid and sensitive structural elucidation of oligosaccharides. <i>Anal Chem.</i> 1999 Sep 1;71(17):3747-54.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520		ATTY. DOCKET NO.: M0656.70089US02	
				FILING DATE: January 16, 2004		CONFIRMATION NO.: 7043	
				APPLICANT: Venkataraman et al.			
				GROUP ART UNIT: 2863		EXAMINER: Tung S. Lau	
Sheet	8	of	13				

*	TUMOVA et al., Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. <i>Int J Biochem Cell Biol.</i> 2000 Mar;32(3):269-88.
*	TURNBULL et al., A strategy for rapid sequencing of heparan sulfate and heparin saccharides. <i>Proc Natl Acad Sci U S A.</i> 1999 Mar 16;96(6):2698-703.
*	VAN KUIK et al., A <sup>1</sup> H NMR database computer program for the analysis of the primary structure of complex carbohydrates. <i>Carbohydr Res.</i> 1992 Nov 4;235:53-68.
*	VAN KUIK et al., Databases of complex carbohydrates. <i>Trends Biotechnol.</i> 1992 Jun;10(6):182-5.
*	VENKATARAMAN et al., A stereochemical approach to pyranose ring flexibility: its implications for the conformation of dermatan sulfate. <i>Proc Natl Acad Sci U S A.</i> 1994 Jun 21;91(13):6171-5.
*	VENKATARAMAN et al., Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans. <i>Proc Natl Acad Sci U S A.</i> 1999 Mar 2;96(5):1892-7.
*	VIVES et al., Sequence analysis of heparan sulphate and heparin oligosaccharides. <i>Biochem J.</i> 1999 May 1;339 ( Pt 3):767-73.
*	VLODAVSKY et al., Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. <i>Nat Med.</i> 1999 Jul;5(7):793-802.
*	WARNICK et al., Purification of an unusual -glucuronidase from flavobacteria. <i>Biochemistry.</i> 1972 Feb 15;11(4):568-72.
*	WEILER et al., Heparin and modified heparin inhibit complement activation in vivo. <i>J Immunol.</i> 1992 May 15;148(10):3210-5.
*	YAMADA et al., Structural studies on the tri- and tetrasaccharides isolated from porcine intestinal heparin and characterization of heparinase/heparitinases using them as substrates. <i>Glycobiology.</i> 1994 Feb;4(1):69-78.
*	YAMADA et al., Isolation of the porcine heparin tetrasaccharides with glucuronate 2-O-sulfate. Heparinase cleaves glucuronate 2-O-sulfate-containing disaccharides in highly sulfated blocks in heparin. <i>J Biol Chem.</i> 1995 Apr 14;270(15):8696-705.
*	YAMADA et al., Structural studies of octasaccharides derived from the low-sulfated repeating disaccharide region and octasaccharide serines derived from the protein linkage region of porcine intestinal heparin. <i>Biochemistry.</i> 1999 Jan 12;38(2):838-47.
*	YANG et al., Glycosylation in human thyroglobulin: location of the N-linked oligosaccharide units and comparison with bovine thyroglobulin. <i>Arch Biochem Biophys.</i> 1996 Mar 1;327(1):61-70.
*	YATES et al., <sup>1</sup> H and <sup>13</sup> C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. <i>Carbohydr Res.</i> 1996 Nov 20;294:15-27.
*	ZHOU et al., Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. <i>J Cell Sci.</i> 2001 Nov;114(Pt 22):4095-103.
*	HOOKE et al., High resolution glycoform analysis of recombinant human interferon-gamma during batch cultures of Chinese hamster ovary cells. <i>Animal Cell Technology: Basic &amp; Applied Aspects, Proceedings of the Annual Meeting of the Japanese Association for Animal Cell Technology, 8th, Fukuoka, November 6-10, 1995, University of Kent, Canterbury, UK. (Abstract only).</i>
*	PACKER et al., Proteome analysis of glycoforms: a review of strategies for the microcharacterization of glycoproteins separated by two-dimensional polyacrylamide gel electrophoresis. <i>Electrophoresis.</i> 1997; 18(3-4):452-460 (Abstract only).

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520	ATTY. DOCKET NO.: M0656.70089US02
				FILING DATE: January 16, 2004	CONFIRMATION NO.: 7043
				APPLICANT: Venkataraman et al.	
				GROUP ART UNIT: 2863	EXAMINER: Tung S. Lau
Sheet	9	of	13		

	*	KLAUSEN et al., Analysis of the glycoforms of human recombinant factor VIIa by capillary electrophoresis and high-performance liquid chromatography. J of Chromatography. 1995; 718(1):195-202. (Abstract only).	
	*	PAREKH, Glycoform analysis of glycoproteins, Methods in Enzymology (GUIDE TO TECHNIQUES). 1994; 230:340-8. (Abstract only).	
	*	KINOSHITA et al., Comparative studies on the analysis of glycosylation heterogeneity of sialic acid-containing glycoproteins using capillary electrophoresis. J of Chromatography. 2000 Jan 14; 866(2):261-71. (Abstract only).	
	*	YIM et al., Capillary zone electrophoretic resolution of recombinant human bone morphogenetic protein 2 glycoforms. An investigation into the separation mechanisms for an exquisite separation. J of Chromatography. 1995 Nov 17; 716(1-2):401-12. (Abstract only).	
	*	PANTAZAKI et al., Recent advances in the capillary electrophoresis of recombinant glycoproteins. Analytica Chimica Acta. 1999; 383(1-2):137-156. (Abstract only).	
	*	CIFUENTES et al., Capillary isoelectric focusing of erythropoietin glycoforms and its comparison with flat-bed isoelectric focusing and capillary zone electrophoresis. J of Chromatography. 1999; 830(2):453-463. (Abstract only).	
	*	TAVERNA et al., Electrophoretic methods for process monitoring and the quality assessment of recombinant glycoproteins. Electrophoresis. 1998; 19(15):2572-2594. (Abstract only).	
	*	GOLDMAN et al., Monitoring recombinant human interferon-gamma N-glycosylation during perfused fluidized-bed and stirred-tank batch culture of CHO cells. Biotechnology and Bioengineering. 1998; 60(5):596-607. (Abstract only).	
	*	ZHOU et al., Application of capillary electrophoresis, liquid chromatography, electrospray-mass spectrometry, and matrix-assisted laser desorption/ionization - time of flight - mass spectrometry to the characterization of recombinant human erythropoietin. Electrophoresis. 1998; 19(13):2348-2355. (Abstract only).	
	*	FUKAZAWA, Sugar chain alterations of glycoproteins in spent culture media of human hepatocellular carcinoma cell lines analyzed by lectin-affinity electrophoresis. Okayama Igakkai Zasshi. 1998; 110(1-6):53-60. (Abstract only).	
	*	VAN DIJK et al., Glycosylation of a1-acid glycoprotein (orosomucoid) in health and disease: occurrence, regulation and possible functional implications. Trends in Glycoscience and Glycotechnology. 1998; 10(53):235-245 (Abstract only).	
	*	ZHANG et al., Quantitative analysis and process monitoring of site-specific glycosylation microheterogeneity in recombinant human interferon-g from Chinese hamster ovary cell culture by hydrophilic interaction chromatography. Journal of Chromatography, B: Biomedical Sciences and Applications. 1998; 712(1 + 2):73-82. (Abstract only).	
	*	PACKER et al., Analyzing glycoproteins separated by two-dimensional gel electrophoresis. Electrophoresis. 1998; 19(6):981-988. (Abstract only).	
	*	ROUTIER et al., Quantitation of the different oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods. Journal of Immunological Methods. 1998; 213(2):113-130. (Abstract only).	
	*	NOVOTNY, Capillary electrophoresis of carbohydrates. Chemical Analysis (High-Performance Capillary Electrophoresis). 1998; 146:729-765. (Abstract only).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520		ATTY. DOCKET NO.: M0656.70089US02	
				FILING DATE: January 16, 2004		CONFIRMATION NO.: 7043	
				APPLICANT: Venkataraman et al.			
				GROUP ART UNIT: 2863		EXAMINER: Tung S. Lau	
Sheet	10	of	13				

*	KLEINDIENST et al., Capillary electrophoresis of peptides and proteins in fused-silica capillaries coated with derivatized polystyrene nanoparticles. Electrophoresis. 1998; 19(2):262-269. (Abstract only).	
*	WANG et al., Mass spectrometric characterization and glycosylation profile of bovine pancreatic bile salt-activated lipase. Protein Expression and Purification. 1998; 12(2):259-268. (Abstract only).	
*	BUTTERS et al., Structural characterization of the N-linked oligosaccharides derived from HIV gp120 expressed in lepidopteran cells. Glycoconjugate Journal. 1998; 15(1):83-88. (Abstract only).	
*	BATEMAN et al., Characterization of protein glycoforms by capillary-zone electrophoresis-nanoelectrospray mass spectrometry. J of Chromatography. 1998; 794(1 + 2):327-344. (Abstract only).	
*	ODA et al., Capillary electrophoresis-based separation of transferrin sialoforms in patients with carbohydrate-deficient glycoprotein syndrome. Electrophoresis. 1997; 18(10):1819-1826. (Abstract only).	
*	KARLSSON et al., The glycosylation of rat intestinal Muc2 mucin varies between rat strains and the small and large intestine. A study of O-linked oligosaccharides by a mass spectrometric approach. Journal of Biological Chemistry. 1997; 272(43):27025-27034. (Abstract only).	
*	HOFFMANN et al., Molecular characterization of b-trace protein in human serum and urine: a potential diagnostic marker for renal diseases. Glycobiology. 1997; 7(4):499-506. (Abstract only).	
*	YAMADA et al., Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconjugate Journal. 1997; 14(3):401-405. (Abstract only).	
*	Analysis of human serum transferrin glycoforms. Anon. LC-GC (1997), 15(4), 370.	
*	HSU et al., Differential N-glycan patterns of secreted and intracellular IgG produced in Trichoplusia ni cells. Journal of Biological Chemistry. 1997; 272(14):9062-9070. (Abstract only).	
*	IOURIN et al., The identification of abnormal glycoforms of serum transferrin in carbohydrate deficient glycoprotein syndrome type I by capillary zone electrophoresis. Glycoconjugate Journal. 1996; 13(6):1031-1042. (Abstract only).	
*	MORRIS et al., Gender-specific glycosylation of human glycodelin affects its contraceptive activity. Journal of Biological Chemistry. 1996; 271(50):32159-32167. (Abstract only).	
*	YANG et al., Capillary isoelectric focusing-electrospray ionization mass spectrometry for transferrin glycoforms analysis. Analytical Biochemistry. 1996; 243(1):140-149. (Abstract only).	
*	CHEN, Capillary electrophoretic analysis of glycoform of glycoproteins. Fushun Shiyou Xueyuan Xuebao. 1996; 16(3):68-69. (Abstract only).	
*	IWASE et al., Estimation of the number of O-linked oligosaccharides per heavy chain of human serum IgA1 by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) analysis of the hinge glycopeptide. Journal of Biochemistry (Tokyo). 1996; 120(2):393-397. (Abstract only).	
*	IWASE et al., Abundance of Galb1,3GalNAc in O-linked oligosaccharide on hinge region of polymerized IgA1 and heat-aggregated IgA1 from normal human serum. Journal of Biochemistry (Tokyo). 1996; 120(1):92-97. (Abstract only).	
*	HONDA, Application of capillary electrophoresis to the analyses of carbohydrates and glycoproteins. Seibutsu Butsuri Kagaku. 1996; 40(3):147-154. (Abstract only).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP:609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520	ATTY. DOCKET NO.: M0656.70089US02
				FILING DATE: January 16, 2004	CONFIRMATION NO.: 7043
				APPLICANT: Venkataraman et al.	
				GROUP ART UNIT: 2863	EXAMINER: Tung S. Lau
Sheet	11	of	13		

	*	THORNTON et al., Respiratory mucins: identification of core proteins and glycoforms. Biochemical Journal. 1996; 316(3):967-975. (Abstract only).	
	*	OGONAH et al., Characterization and analysis of human interferon-g glycoforms produced in baculovirus infected Spodoptera frugiperda (Sf9) and Estigmene acrea (Ea) cell lines. Animal Cell Technology: Developments towards the 21st Century, [Proceedings of the Meeting], Veldhoven, Neth., Sept. 12-16, 1994. (Abstract only).	
	*	HANISCH et al., MUC1 glycoforms in breast cancer. Cell line T47D as a model for carcinoma-associated alterations of O-glycosylation. European Journal of Biochemistry. 1996; 236(1):318-27. (Abstract only).	
	*	BURLINGAME, Characterization of protein glycosylation by mass spectrometry. Current Opinion in Biotechnology. 1996; 7(1):4-10. (Abstract only).	
	*	KELLY et al., Development of electrophoretic conditions for the characterization of protein glycoforms by capillary electrophoresis-electrospray mass spectrometry. Journal of Chromatography. 1996; 720(1 + 2):409-27. (Abstract only).	
	*	KAKEHI et al., Analysis of glycoproteins, glycopeptides and glycoprotein-derived oligosaccharides by high-performance capillary electrophoresis. Journal of Chromatography. 1996; 720(1 + 2):377-93. (Abstract only).	
	*	LEGAZ et al., Effect of polyamines on the separation of ovalbumin glycoforms by capillary electrophoresis. Journal of Chromatography. 1996; 719(1):159-70. (Abstract only).	
	*	ROBERTS et al., An Integrated Strategy for Structural Characterization of the Protein and Carbohydrate Components of Monoclonal Antibodies: Application to Anti-Respiratory Syncytial Virus MAb. Analytical Chemistry. 1995; 67(20):3613-25. (Abstract only).	
	*	MACKIEWICZ et al., Glycoforms of serum a1-acid glycoprotein as markers of inflammation and cancer. Glycoconjugate Journal. 1995; 12(3):241-7. (Abstract only).	
	*	VAN DIJK et al., a1-Acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function. Glycoconjugate Journal. 1995; 12(3):227-33. (Abstract only).	
	*	DE REGGI et al., The glycan moiety of human pancreatic lithostathine. Structure characterization and possible pathophysiological implications. European Journal of Biochemistry. 1995; 230(2):503-10. (Abstract only).	
	*	PIRIE-SHEPHERD et al., Sialic acid content of plasminogen 2 glycoforms as a regulator of fibrinolytic activity. Isolation, carbohydrate analysis, and kinetic characterization of six glycoforms of plasminogen 2. Journal of Biological Chemistry. 1995; 270(11):5877-81. (Abstract only).	
	*	WU et al., Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120 and the role of glycosylation in the correct folding of the V1/V2 domain. Journal of Virology. 1995; 69(4):2271-8. (Abstract only).	
	*	OGONAH et al., Analysis of human interferon-g glycoforms produced in baculovirus infected insect cells by matrix assisted laser desorption spectrometry. Biochemical Society Transactions. 1995; 23(1):100S. (Abstract only).	
	*	JENKINS, Monitoring and control of recombinant glycoprotein heterogeneity in animal cell cultures. Biochemical Society Transactions. 1995; 23(1):171-5. (Abstract only).	
	*	VAN DER LINDEN et al., Preparative affinity electrophoresis of different glycoforms of serum glycoproteins: Application for the study of inflammation-induced expression of sialyl-Lewisx groups on a1-acid glycoprotein (orosomucoid). Glycosylation & Disease. 1994; 1(1):45-52. (Abstract only).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520	ATTY. DOCKET NO.: M0656.70089US02
				FILING DATE: January 16, 2004	CONFIRMATION NO.: 7043
				APPLICANT: Venkataraman et al.	
				GROUP ART UNIT: 2863	EXAMINER: Tung S. Lau
Sheet	12	of	13		

	*	ANDERSEN et al., Monosaccharide and oligosaccharide analysis of isoelectric focusing-separated and blotted granulocyte colony-stimulating factor glycoforms using high-pH anion-exchange chromatography with pulsed amperometric detection. <i>Glycobiology</i> . 1994; 4(4):459-67. (Abstract only).	
	*	MEDZIHRADESKY et al., Characterization of protein N-glycosylation by reversed-phase microbore liquid chromatography/electrospray mass spectrometry, complementary mobile phases, and sequential exoglycosidase digestion. <i>Journal of the American Society for Mass Spectrometry</i> . 1994; 5(5):350-8. (Abstract only).	
	*	PEDERSEN et al., Characterization of proteinase A glycoforms from recombinant <i>Saccharomyces cerevisiae</i> . <i>Biotechnology and Applied Biochemistry</i> . 1993; 18(3):377-88. (Abstract only).	
	*	MUELLER et al., Characterization and direct glycoform profiling of a hybrid plasminogen activator by matrix-assisted laser desorption and electrospray mass spectrometry: correlation with high-performance liquid chromatographic and nuclear magnetic resonance analyses of the released glycans. <i>Biological Mass Spectrometry</i> . 1994; 23(6):330-8. (Abstract only).	
	*	DUFFIN et al., Identification and oligosaccharide structure analysis of rhodopsin glycoforms containing galactose and sialic acid. <i>Glycobiology</i> . 1993; 3(4):365-380. (Abstract only).	
	*	MACKIEWICZ et al., Glycoforms of $\alpha$ 1-acid glycoprotein as disease markers. <i>Acute Phase Proteins</i> . 1993; 651-61. (Abstract only).	
	*	RUDD et al., Glycoforms modify the dynamic stability and functional activity of an enzyme. <i>Biochemistry</i> . 1994; 33(1):17-22. (Abstract only).	
	*	CLOGSTON et al., Glycosidase digestion, electrophoresis and chromatographic analysis of recombinant human granulocyte colony-stimulating factor glycoforms produced in Chinese hamster ovary cells. <i>Journal of Chromatography</i> . 1993; 637(1):55-62. (Abstract only).	
	*	COCO-MARTIN et al., Analysis of glycoforms present in two mouse IgG2a monoclonal antibody preparations. <i>Journal of Immunological Methods</i> . 1992; 155(2):241-8. (Abstract only).	
	*	IWASE et al., Analysis of glycoform of O-glycan from human myeloma immunoglobulin A1 by gas-phase hydrazinolysis following pyridylation of oligosaccharides. <i>Analytical Biochemistry</i> . 1992; 206(1):202-5. (Abstract only).	
	*	RUDD et al., Separation and analysis of the glycoform populations of ribonuclease B using capillary electrophoresis. <i>Glycoconjugate Journal</i> . 1992; 9(2):86-91. (Abstract only).	
	*	TREUHEIT et al., Analysis of the five glycosylation sites of human $\alpha$ 1-acid glycoprotein. <i>Biochemical Journal</i> . 1992; 283(1):105-12. (Abstract only).	
	*	YIM, Fractionation of the human recombinant tissue plasminogen activator (rtPA) glycoforms by high-performance capillary zone electrophoresis and capillary isoelectric focusing. <i>Journal of Chromatography</i> . 1991; 559(1-2):401-10. (Abstract only).	
	*	HEFTA et al., Sequence and glycosylation site identity of two distinct glycoforms of nonspecific cross-reacting antigen as demonstrated by sequence analysis and fast atom bombardment mass spectrometry. <i>Journal of Biological Chemistry</i> . 1990; 265(15):8618-26. (Abstract only).	
	*	O'HARE et al., Glycoforms of human serum proteins identified by Ricinus communis lectin. <i>Biochemical Society Transactions</i> . 1990; 18(2):323. (Abstract only).	
	*	JANSKA et al., The lower molecular weight acid phosphatase from the frog liver: isolation of homogeneous AcPase III and IV representing glycoforms with different bioactivity. <i>Comparative Biochemistry and Physiology, Part B: Biochemistry &amp; Molecular Biology</i> . 1989; 92B(2):341-6. (Abstract only).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/759,520	ATTY. DOCKET NO.: M0656.70089US02
				FILING DATE: January 16, 2004	CONFIRMATION NO.: 7043
				APPLICANT: Venkataraman et al.	
				GROUP ART UNIT: 2863	EXAMINER: Tung S. Lau
Sheet	13	of	13		

	*	ZENG et al., Characterization and analysis of a novel glycoprotein from snake venom using liquid chromatography-electrospray mass spectrometry and Edman degradation. European Journal of Biochemistry/FEBS. 1999 Dec; 266(2):352-8. (Abstract only).	
--	---	---	--

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/356,349, filed January 31, 2003, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.